NeoChord, Inc. Appoints New Chief Executive Officer to Lead Commercialization Efforts and Study Novel First-Line Therapy for Mitral Valve Regurgitation
MINNEAPOLIS, Feb. 22, 2024 /PRNewswire/ -- NeoChord is a privately held, medical technology company and the world-leader in beating heart delivery of artificial chords in the treatment of mitral valve regurgitation.
- MINNEAPOLIS, Feb. 22, 2024 /PRNewswire/ -- NeoChord is a privately held, medical technology company and the world-leader in beating heart delivery of artificial chords in the treatment of mitral valve regurgitation.
- The company appointed Todd Berg as Chief Executive Officer to oversee clinical and commercial programs for transeptal and transapical repair of damaged mitral valve chords resulting in regurgitation.
- Berg has over 30 years of experience successfully developing and commercializing novel medical therapies and holds over 100 U.S. patents.
- The opportunity to develop a first-line therapy for mitral valve disease, by resolving regurgitation early in the disease state, is incredibly compelling," said Berg.